The newest research findings create "tangible benchmarks" for how earlier treatment can lead to better outcomes, said Dr. Kim. In an interview with Esther Lee Kim, MD, from Orange County Retina in ...
A panelist discusses how interpreting clinical trial data, monitoring disease progression, and maintaining transparent communication help retina specialists make informed decisions about when and how ...
Ashkan Abbey, MD, FASRS, FAAO, from Texas Retina Associates discussed EYP-1901, an innovative intravitreal insert that releases vorolanib, a potent tyrosine kinase inhibitor designed to treat retinal ...
The topical therapy offers a less invasive approach to corneal cross-linking, with commercial availability anticipated in early 2026. Glaukos announced FDA approval for its novel topical therapy ...
A panelist discusses how retina specialists, residents, and fellows manage geographic atrophy by emphasizing early diagnosis, navigating new anticomplement therapies, and improving patient ...
David R. Lally, MD, discusses promising results from the ARCHER trial on ANX007 for age-related macular degeneration, emphasizing the need for vision-preserving treatments. Note: The following ...
This year, 18 presenters will deliver named lectures during the American Academy of Ophthalmology meeting. Lee M. Jampol, MD, will deliver the lecture “How to Describe New Diseases, the Same Skills ...
A panelist discusses how retina specialists, residents, and fellows manage geographic atrophy by emphasizing early diagnosis, navigating new anticomplement therapies, and improving patient ...
Positive pediatric data emerge from the OPGx-LCA5 phase 1/2 trial of Leber congenital amaurosis type 5 ...
Breye Therapeutics advances danegaptide, a novel oral therapy for non-proliferative diabetic retinopathy, showing promise in early clinical trials. Breye Therapeutics announced the successful ...
Proactive communication and leveraging advanced, yet reliable, technologies to maximize efficiency are essential pillars of success. Subspecialist ophthalmologists in rural areas face unique ...
The 40-week phase 2 clinical trial was a multicenter, chronic dosing trial for the evaluation of the safety and efficacy of subcutaneous MGB, “an investigational VEGF receptor tyrosine kinase ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback